ImmuCell (NASDAQ:ICCC) Issues Quarterly Earnings Results

ImmuCell (NASDAQ:ICCC – Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05, FiscalAI reports. The business had revenue of $8.04 million for the quarter, compared to analyst estimates of $5.40 million. ImmuCell had a return on equity of 2.69% and a net margin of 2.57%.

ImmuCell Stock Up 0.3%

Shares of ImmuCell stock traded up $0.03 during trading hours on Thursday, hitting $10.22. The company had a trading volume of 19,294 shares, compared to its average volume of 5,576. ImmuCell has a twelve month low of $4.52 and a twelve month high of $12.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.75 and a quick ratio of 2.71. The company has a market cap of $92.82 million, a P/E ratio of 127.77 and a beta of 0.61. The company’s 50-day moving average is $10.08 and its two-hundred day moving average is $9.01.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered ImmuCell from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Get Our Latest Stock Analysis on ICCC

About ImmuCell

(Get Free Report)

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle. ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.

Read More

Earnings History for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.